Form 4: Avidity Director Sells Shares, Options in Novartis Merger

Avidity Biosciences director Noreen Henig disposed of all common stock and stock options as part of the company's acquisition by Novartis AG for $72.00 per share.

Summary

• Noreen Henig, a Director of Avidity Biosciences, Inc., reported the disposition of all her beneficial ownership in the company.
• This includes 6,692 shares of common stock, inclusive of shares issuable upon settlement of previously reported restricted stock units.
• Additionally, 103,380 stock options with various exercise prices ranging from $0.42 to $39.96 were disposed of.
• These transactions occurred on February 27, 2026, and were executed pursuant to the Agreement and Plan of Merger dated October 25, 2025.
• Under the merger agreement, Novartis AG is acquiring Avidity Biosciences, Inc.
• Stock options were exchanged for a cash payment equal to the difference between the merger consideration of $72.00 per share and the option's exercise price.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Avidity Biosciences shareholders, as it confirms the execution of a lucrative merger agreement, leading to a profitable exit for the company's equity holders and option holders.

Positives

• The disposition of options at a premium to their exercise price indicates a profitable outcome for the option holder due to the merger consideration of $72.00 per share.
• The merger with Novartis AG suggests a successful strategic outcome for Avidity Biosciences, Inc. and its shareholders.

Negatives

• The complete disposition of shares and options by a director signifies the end of their direct equity interest in Avidity Biosciences, Inc. as an independent entity.
• Avidity Biosciences, Inc. will no longer trade independently following the merger.

Future Outlook

The filing indicates the impending acquisition of Avidity Biosciences, Inc. by Novartis AG, suggesting that Avidity Biosciences, Inc. will cease to be an independent publicly traded entity.

Industry Context

StockSavvy.ai notes that this acquisition by Novartis AG highlights the ongoing consolidation trend within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies often acquire innovative smaller biotechs to bolster their pipelines and intellectual property. This specific transaction indicates a successful exit for Avidity Biosciences, Inc. and its shareholders.

Comparison to Industry Standards

• The acquisition price of $72.00 per share for Avidity Biosciences, Inc. by Novartis AG can be compared to recent biotech acquisitions, such as Pfizer's acquisition of Seagen for $43 billion ($229 per share) or Merck's acquisition of Prometheus Biosciences for $10.8 billion ($200 per share). While the per-share price differs, the underlying principle of a premium paid for innovative assets is consistent with industry standards for successful biotech exits.
• The disposition of director holdings post-merger agreement is standard practice in M&A transactions, ensuring a clean transfer of ownership.

Management Changes

Stakeholder Impact

• Shareholders: Existing shareholders of Avidity Biosciences, Inc. will receive $72.00 per share in cash, representing a clear exit and likely a premium.
• Employees: While not explicitly stated, mergers often lead to integration and potential restructuring, which could impact employees.
• Management: Management, including directors like Noreen Henig, are cashing out their equity, indicating a successful outcome for them.

Next Steps

• Completion of the merger between Avidity Biosciences, Inc. and Novartis AG.
• Avidity Biosciences, Inc. will cease to be an independent publicly traded company.

Key Dates

Recommendation

The filing details a director's disposition of shares and options in anticipation of the Avidity Biosciences, Inc. acquisition by Novartis AG at $72.00 per share. With a definitive merger agreement in place and the transaction date set, the stock is expected to trade near the acquisition price. Therefore, a "hold" recommendation is appropriate for existing shareholders awaiting the cash payout, as significant price appreciation is unlikely, and the downside risk is primarily tied to the merger's completion.

Keywords

Avidity Biosciences, RNAM, Novartis AG, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Common Stock, Director, Beneficial Ownership